CANCER BREAKTHROUGH? Melanoma trial shows 49% REDUCTION in relapse risk

Moderna’s Flu Vaccine & Future Outlook: A Detailed Summary

Key Concepts:

• mRNA Technology: Utilizing messenger RNA to instruct cells to produce proteins, triggering an immune response.
• BLA (Biologics License Application): Application submitted to the FDA for approval of a biologic product (like a vaccine).
• Phase 3 Study: Large-scale clinical trial to assess vaccine efficacy and safety.
• Egg-Adapted Virus: Mutation of influenza viruses during egg-based vaccine production, potentially reducing vaccine effectiveness.
• Operation Warp Speed: US government initiative to accelerate the development, production, and distribution of COVID-19 vaccines.
• Personalized Cancer Vaccines: Vaccines tailored to an individual’s tumor mutations, aiming to stimulate an immune response against cancer cells.
• Post-Market Study: Studies conducted after a drug or vaccine is approved to gather additional information about its effects in a larger population.
• Warp Speed: A government program to accelerate the development of vaccines and therapeutics.

I. Flu Vaccine Application & FDA Review

Moderna’s application for full FDA approval of its mRNA-based influenza vaccine for adults aged 50-64 is back on track. The FDA has agreed to review the Biologics License Application (BLA) following a two-week consultation period with Moderna. The FDA’s decision date is now August 5th. This follows an initial notification from the FDA two weeks prior that they would not initiate the review, a surprising development given prior alignment on the Phase 3 study design. Moderna addressed the FDA’s concerns by proposing modifications to the application and committing to a post-approval required study to further confirm Phase 3 results. Dr. Stephen Hoge, President of Moderna, emphasized that the initial discussions regarding this vaccine began five years ago, with close collaboration with regulators to ensure alignment before significant investment (over $1 billion) in Phase 3 trials.

II. Challenges with Traditional Flu Vaccine Production

Dr. Hoge highlighted significant limitations of current influenza vaccine manufacturing processes. Approximately 96% of flu vaccines are produced using eggs. This method presents two key challenges:

• Strain Selection Timing: Strains for the vaccine must be selected as early as February, potentially leading to a mismatch between the vaccine and circulating strains by the winter season. Approximately half the time, the selected strain proves incorrect.
• Egg Adaptation: The process of growing viruses in eggs can cause mutations (egg adaptation), further reducing the vaccine’s effectiveness. This means the vaccine administered in the fall may not optimally match the prevalent strains during the winter.

Moderna’s mRNA platform offers a potential solution by allowing strain selection as late as May or June, mirroring the process used for COVID-19 vaccines, and avoiding the egg-adaptation issue.

III. Investment & Regulatory Uncertainty

Moderna temporarily scaled back investment in late-stage vaccine trials due to the regulatory delays and uncertainty surrounding FDA approval. Dr. Hoge stressed the importance of “clear and transparent rules” from regulators and consistent application of those rules to encourage continued investment in vaccine development. He warned that arbitrary changes to regulations after trials are completed can deter companies from undertaking large-scale research and development projects. The company is prioritizing maturing its business and achieving profitability before reinvesting heavily in new vaccine trials.

IV. COVID-19 Vaccine Success & Lessons Learned

The rapid development and deployment of Moderna’s COVID-19 vaccine (less than 10 months) demonstrated the potential of mRNA technology. This success was facilitated by President Trump’s Operation Warp Speed, which provided funding and streamlined the regulatory process. Dr. Hoge noted that an Executive Order signed by President Trump in 2019, calling for the modernization of vaccine manufacturing, particularly for influenza, also contributed to the accelerated COVID-19 vaccine development. However, the discussion touched upon a point of contention regarding the Biden administration’s approach, with a question raised about whether the emphasis on vaccines led to the discouragement of exploring other potential COVID-19 treatments. Dr. Hoge stated he could not comment on the administration’s intentions but emphasized the need to demonstrate a high unmet medical need for vaccine approval.

V. Cancer Vaccine Breakthroughs & Future Growth

Moderna is making significant strides in cancer vaccine development. Positive five-year data from a combination vaccine (Moderna & Merck) used with Keytruda showed a 49% reduction in the risk of recurrence or death in melanoma patients. Phase 3 trials are underway for multiple tumor types, including renal cell carcinoma, bladder cancer, pancreatic cancer, and gastric cancer. Initial results are expected in the next 12 months. Dr. Hoge described this as a potentially “dramatic change” in cancer treatment.

Moderna’s CEO, Stéphane Bancel, indicated that future growth will be driven by international expansion, particularly in Canada, the UK, Australia, Latin America, and Asia. The company anticipates full-year revenue growth of up to 10%, targeting $4.9 billion in operating expenses. Moderna is focusing on cost control and prioritizing R&D investment.

VI. International Expansion & Manufacturing

Moderna has received European Commission approval for its new COVID-19 vaccine, becoming the third authorized vaccine in the EU. International growth is currently the primary driver of revenue. While manufacturing primarily occurs in the US, Moderna has facilities in Canada, the UK, and Australia to support expansion in those markets. The company is also adapting to a shift in the US, where the government will begin selecting influenza vaccine compositions tailored specifically for the American population, potentially allowing Moderna to contribute a vaccine designed for circulating US strains.

Notable Quotes:

• Dr. Stephen Hoge: “What we need are clear and transparent rules from the regulators, clear objectives that we're aiming and we need those consistently applied.”
• Dr. Stephen Hoge: “It’s important to give credit where it’s due. There was a tremendous amount of work beforehand.” (referring to pre-pandemic vaccine research)
• Stéphane Bancel: “Most of the growth will come from growth in international.”

This summary provides a detailed overview of the key points discussed in the interview, preserving the technical language and specific details presented by Dr. Hoge and referencing information from Moderna’s CEO, Stéphane Bancel. It highlights the challenges and opportunities facing Moderna as it navigates the regulatory landscape and expands its pipeline beyond COVID-19 vaccines.